How HRT Affects Blood Pressure: What You Need to Know

Hormone replacement therapy can raise, lower, or leave blood pressure unchanged depending on the formulation, the delivery route, and whether you already have high blood pressure. That may sound like a non-answer, but the variability is the story. Transdermal estrogen paired with micronized progesterone tends to nudge blood pressure down or hold it steady, while older oral estrogen formulations have a more complicated track record. The details matter more here than the headline, and they diverge sharply from the blanket warnings many women still hear.

Why Menopause Itself Pushes Blood Pressure Up

Before looking at what HRT does, it helps to know what menopause does without treatment. The drop in estrogen that comes with menopause affects blood vessels directly. A large UK Biobank analysis of women found that postmenopausal women had significantly higher arterial stiffness than premenopausal women, and menopause itself was independently associated with that increase even after adjusting for age and other risk factors.¹ Stiffer arteries resist blood flow more, which pushes systolic pressure higher. Menopause also disrupts the normal nighttime drop in blood pressure, a pattern linked to greater cardiovascular risk over time.²

This is the backdrop against which HRT operates. The therapy is not being layered onto a stable cardiovascular system; it is being introduced at a point when blood pressure is already trending upward for hormonal reasons. That context explains why some studies find HRT is associated with lower blood pressure compared to untreated menopause, even if it would not lower blood pressure in a younger woman who still has her own estrogen supply.

How Estrogen Relaxes Blood Vessels

Estrogen has a rapid, direct effect on the inner lining of blood vessels. Within minutes of exposure, estrogen activates an enzyme in endothelial cells that produces nitric oxide, the molecule that signals surrounding smooth muscle to relax and widen the vessel.³ This happens through a signaling chain where estrogen triggers a protein called Akt, which in turn switches on the nitric oxide-producing enzyme.⁴ Progesterone also contributes to nitric oxide production, though through partially overlapping pathways.⁵

The takeaway for blood pressure is straightforward: estrogen promotes blood vessel relaxation. That is one of the reasons why premenopausal women generally have lower blood pressure than men of the same age, and why its loss at menopause shifts the cardiovascular picture. HRT, in principle, restores some of that vascular protection. Whether it does so cleanly in practice depends heavily on how the hormones are delivered.

Oral Versus Transdermal Delivery

The route by which estrogen enters your body turns out to be one of the most important variables for blood pressure. Oral estrogen passes through the liver before reaching the rest of the circulation. That “first pass” triggers the liver to ramp up production of angiotensinogen, a protein that feeds into the hormonal system controlling blood pressure and fluid balance. One study found that oral estrogen increased angiotensinogen levels by about 58%, while transdermal estrogen did not raise it at all.⁶ Both routes suppressed renin (an enzyme that kicks off the blood-pressure-raising cascade) by about 30%, but only oral estrogen simultaneously poured more raw material into that cascade through the angiotensinogen spike.

In clinical terms, this biochemical difference translates into measurably different blood pressure outcomes. A study comparing the two routes found that transdermal HRT significantly lowered diastolic and mean blood pressure, while oral HRT left blood pressure essentially unchanged.⁷ A broader review of the evidence confirmed that transdermal estrogen combined with micronized progesterone had a beneficial effect on blood pressure in women with normal readings and, at worst, a neutral effect in women with existing hypertension.⁸

This distinction is worth emphasizing because many of the older studies that raised alarm about HRT and blood pressure used oral conjugated equine estrogens, often paired with synthetic progestins. The findings from those studies should not be applied wholesale to modern transdermal regimens. The historical perception that HRT raises blood pressure was largely shaped by oral contraceptive research, where high-dose synthetic estrogens were the norm. The low replacement doses of natural estrogens used in HRT are a different pharmacological situation.⁹

Why the Progestin Component Matters

Most women with a uterus take estrogen alongside a progestogen to protect the uterine lining. The type of progestogen makes a real difference for blood pressure. A study of postmenopausal Korean women found that when oral conjugated estrogen was given alone, daytime blood pressure rose in women who started with normal readings. Adding micronized progesterone abolished that increase. In women who started with high blood pressure, the combination actually strengthened the drop in systolic pressure seen throughout the day.¹⁰

Part of the reason micronized progesterone helps with blood pressure is its interaction with the body’s fluid regulation. Estrogen can promote sodium and water retention through its effects on aldosterone, the hormone that tells your kidneys to hold onto salt. Some progestogens compete with aldosterone at the receptor level, which counteracts that salt-retaining signal. Not all progestogens do this equally well, and some synthetic progestins can actually worsen cardiovascular risk factors. Choosing the right pairing matters.

A separate study looking at estradiol with and without progesterone found that estradiol alone lowered nighttime systolic blood pressure by about 6 mmHg compared to placebo, with similar reductions in diastolic and mean pressure. Adding progesterone did not produce any further drop in blood pressure but did activate the renin-angiotensin system, suggesting the two hormones pull in slightly different directions on that particular pathway.¹¹ The net effect was still favorable, but it underscores that the progestogen component is not just a bystander in blood pressure terms.

If You Already Have High Blood Pressure

One of the most persistent myths is that women with hypertension should avoid HRT entirely. The evidence tells a different story. A review concluded that HRT does not cause harmful blood pressure effects in women with normal readings and should be safe in hypertensive women, particularly when blood pressure is being managed with antihypertensive medications. In postmenopausal patients with known hypertension who were already on blood pressure medication, a reduction in both systolic and diastolic pressure was typically observed during HRT.¹²

A separate analysis looked specifically at transdermal HRT in nearly 1,400 hypertensive women with diastolic blood pressure above 95 mmHg. Blood pressure dropped by an average of 7 mmHg systolic and 9 mmHg diastolic during treatment. The same paper noted that the risk of developing new hypertension during HRT was very low, though regular blood pressure monitoring was still recommended.¹³ These reductions are clinically meaningful and in the same ballpark as what some blood pressure medications achieve.

If you have hypertension and are considering HRT for menopausal symptoms, the conversation with your clinician should be about which formulation and route, not about whether HRT is categorically off the table. Transdermal estradiol with micronized progesterone has the most reassuring blood pressure profile in this group.

The Nighttime Dipping Pattern

Blood pressure normally drops at night by around 10 to 20 percent. People whose pressure does not dip sufficiently are called “non-dippers,” and this pattern is associated with greater cardiovascular risk. Menopause increases the likelihood of becoming a non-dipper. A study comparing postmenopausal women receiving HRT with untreated women found that 80% of women on HRT had a normal dipping pattern, compared with only 50% of untreated women.²

This finding may not show up on a standard office blood pressure reading, which captures only a snapshot during the day. Twenty-four-hour ambulatory monitoring, where you wear a cuff that inflates periodically throughout the day and night, is the way to see whether HRT is restoring a healthier diurnal pattern. The study measuring estradiol’s effects on ambulatory pressure confirmed that the largest improvements occurred at night, with nocturnal systolic blood pressure about 6 mmHg lower on estradiol compared to placebo.¹¹ Daytime pressure followed the same trend but the difference was smaller.

The Timing Hypothesis

When you start HRT in relation to menopause appears to influence how your cardiovascular system responds. The timing hypothesis holds that estrogen exerts protective effects on healthy blood vessel lining but can have neutral or even adverse effects on vessels that already have established atherosclerotic plaques. Animal research supports this: in mice prone to developing atherosclerosis, estrogen therapy prevented new plaque formation when given at the onset of the process but had no effect on lesions that were already there.¹⁴

For blood pressure specifically, this means women who begin HRT close to menopause, when their arteries are still relatively healthy, are more likely to see beneficial vascular effects than women who start years later, when arterial stiffness and plaque buildup have already progressed. The timing hypothesis also helps explain some of the discordant results in older trials that enrolled women well past menopause and found less cardiovascular benefit.

The Observational Wrinkle

Not all the data on HRT and blood pressure are reassuring. A large observational cohort study found that women who had used menopausal hormone therapy had higher odds of having high blood pressure than non-users. Among women under 56, past use was associated with roughly 60% higher odds; in women aged 56 to 61, the figure was similar. The association weakened with age but persisted, and longer duration of use was tied to higher odds of elevated blood pressure.¹⁵

How do you square this with the clinical trial data showing neutral or beneficial effects? Observational studies cannot establish causation. Women who are prescribed HRT may differ from those who are not in ways that affect blood pressure independently. They may have more severe menopausal symptoms, different baseline health profiles, or be under closer medical surveillance that catches high blood pressure more often. The type of HRT used in the cohort also matters, and many of these women would have been on older oral formulations rather than transdermal estradiol. Still, this study is a reminder that blood pressure monitoring during HRT is not optional. Even if the balance of evidence suggests HRT is unlikely to cause a clinically significant rise in pressure with modern formulations, individual responses vary.

Gender-Affirming Hormone Therapy

The relationship between hormones and blood pressure plays out somewhat differently in gender-affirming care, where the goals and populations are distinct from menopausal HRT.

For transgender women receiving feminizing hormone therapy, the blood pressure news is generally encouraging. Observational data found lower systolic and diastolic blood pressure after a year of estrogen-based treatment. One retrospective study found a roughly 6 mmHg reduction in systolic pressure. Researchers attributed this more to the suppression of testosterone than to estrogen itself, since testosterone levels positively correlated with systolic blood pressure in that population.¹⁶

For transgender men receiving testosterone, the picture reverses. Testosterone therapy consistently raises systolic blood pressure and may raise diastolic pressure as well.¹⁷ A systematic review found that three of seven studies assessing blood pressure detected modest increases or changes that were not clinically significant, but in one study two patients developed overt hypertension that resolved when testosterone was stopped. Testosterone also raises hemoglobin and hematocrit, thickening the blood, which can independently contribute to cardiovascular strain.¹⁸ Regular blood pressure and blood count monitoring are standard practice for people on masculinizing therapy for this reason.

When HRT Is Not the Right Tool

Some women cannot or prefer not to use hormone therapy, whether because of blood pressure concerns, a history of hormone-sensitive cancer, blood clotting disorders, or personal preference. For those whose primary complaint is hot flashes, non-hormonal options now exist. Fezolinetant, approved for the treatment of menopausal vasomotor symptoms, works by blocking a brain signaling molecule called neurokinin B from binding to its receptor in the hypothalamus, which is where the body’s temperature-regulating center goes haywire during menopause. Because it targets the specific brain pathway responsible for hot flashes rather than replacing estrogen systemically, it does not carry the same vascular and metabolic considerations as HRT.¹⁹ A second drug in the same class, elinzanetant, was in late-stage clinical trials at the time of that report.

These drugs do not address the broader cardiovascular and bone-health effects of estrogen loss, so they are not a one-for-one HRT substitute. But for a woman whose main reason for considering HRT is symptom relief and who has uncontrolled hypertension or other reasons to avoid systemic hormones, they represent a genuinely different option rather than a lesser version of the same therapy.

Practical Considerations for Monitoring

If you are starting or already using HRT, blood pressure deserves active attention rather than passive assumption. A few points are worth keeping in mind:

Check early and often: Get a baseline reading before starting HRT. Recheck within one to three months of initiation, then at regular intervals. Home blood pressure monitors are inexpensive and give a more representative picture than occasional clinic visits.
Ask about 24-hour monitoring: A single office reading can miss the nighttime dipping pattern that HRT may improve. If you have borderline hypertension or are concerned about cardiovascular risk, ambulatory monitoring provides more actionable information.
Route matters more than brand: If blood pressure is a concern, transdermal estradiol (patches, gels, or sprays) avoids the liver first-pass effect that drives the angiotensinogen increase seen with oral estrogen.
Progestogen selection counts: Micronized progesterone has a more favorable blood pressure profile than many synthetic progestins. If you need uterine protection, this is the progestogen best supported by blood pressure data.
Existing hypertension is not a dealbreaker: The evidence shows that women with treated hypertension often see their blood pressure drop further on transdermal HRT. The key is that blood pressure should be adequately controlled before starting and monitored consistently afterward.

The gap between what many women are told about HRT and blood pressure and what the data actually show is wider than you might expect. The blanket caution that HRT raises blood pressure was shaped by an era of high-dose oral contraceptives and synthetic hormone formulations. Modern regimens, particularly transdermal estradiol with micronized progesterone, look markedly different in clinical trials. Individual variation is real, and monitoring is non-negotiable, but the starting assumption should be informed by the current evidence rather than inherited anxiety from decades-old formulations.